Source: Journal of Allergy and Clinical Immunology: Global. Unidade: FMRP
Subjects: DERMATITE, ANTÍGENOS, LINFÓCITOS T, IMUNIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARRUDA, Luisa Karla de Paula et al. Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: a role of type 2 inflammation?. Journal of Allergy and Clinical Immunology: Global, v. 2, n. 1, p. 114-117, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.jacig.2022.08.004. Acesso em: 27 nov. 2025.APA
Arruda, L. K. de P., Cordeiro, D. L., Langer, S. S., Koenigkam-Santos, M., Calado, R. T., Dias, M. M., et al. (2023). Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: a role of type 2 inflammation? Journal of Allergy and Clinical Immunology: Global, 2( 1), 114-117. doi:10.1016/j.jacig.2022.08.004NLM
Arruda LK de P, Cordeiro DL, Langer SS, Koenigkam-Santos M, Calado RT, Dias MM, Anhesini LR, Oliveira JB, Grimbacher B, Ferriani MPL. Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: a role of type 2 inflammation? [Internet]. Journal of Allergy and Clinical Immunology: Global. 2023 ; 2( 1): 114-117.[citado 2025 nov. 27 ] Available from: https://doi.org/10.1016/j.jacig.2022.08.004Vancouver
Arruda LK de P, Cordeiro DL, Langer SS, Koenigkam-Santos M, Calado RT, Dias MM, Anhesini LR, Oliveira JB, Grimbacher B, Ferriani MPL. Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: a role of type 2 inflammation? [Internet]. Journal of Allergy and Clinical Immunology: Global. 2023 ; 2( 1): 114-117.[citado 2025 nov. 27 ] Available from: https://doi.org/10.1016/j.jacig.2022.08.004
